MLX

Across TCGA pan-cancer cohorts, MLX mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MLX data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MLX mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MLX expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where MLX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.979	0.808	.019	19	view →
PDAC	OS	Tertile	III,IV	0.812	0.320	.014	19	view →
HNSC	DFS	Tertile	All	0.623	1.000	.040	10	view →
CCRCC	OS	Quartile	III,IV	0.422	0.871	.036	3	view →
LSCC	DFS	Median	All	0.956	0.920	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MLX–LUAD (DFS)

Open the LUAD breakdown →